Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer (Journal article)

Samantas, E./ Skarlos, D. V./ Pectasides, D./ Nicolaides, P./ Kalofonos, H./ Mylonakis, N./ Vardoulakis, T./ Kosmidis, P./ Pavlidis, N./ Fountzilas, G.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorSamantas, E.en
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorNicolaides, P.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorVardoulakis, T.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.rightsDefault Licence-
dc.subjectAdministration, Oralen
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverseen
dc.subjecteffects/pharmacokinetics/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/pharmacokineticsen
dc.subjectCarcinoma, Small Cell/*drug therapy/mortality/pathology/radiotherapyen
dc.subjectCombined Modality Therapyen
dc.subjectDisease Progressionen
dc.subjectDrug Administration Scheduleen
dc.subjectEtoposide/administration & dosage/pharmacokineticsen
dc.subjectLung Neoplasms/*drug therapy/mortality/pathology/radiotherapyen
dc.subjectMiddle Ageden
dc.subjectRisk Assessmenten
dc.subjectSurvival Analysisen
dc.titleCombination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung canceren
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractSixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and oral Etoposide, at a dose of 100 mg, every other day for 21 days. The treatment was repeated every 5 weeks. Responding patients with LD were also treated with thoracic irradiation and those who achieved complete response (CR) received prophylactic cranial radio-therapy. The overall response rate (RR) was 32.1% with 8.9% CR. The responses were better for LD (RR 58.3%, CR 25%, partial response, PR 33.3%), than those for ED (RR 25%, CR 4.5%, PR 20.5%). The median time to progression (TTP) was 4.8 months and the median survival 5.5 months. These poor results could be attributed to the bad performance status and the presence of visceral and brain metastases in this group of patients. The results could also be due to the lower maximum concentration (Cmax) and higher T1/2 of Etoposide, as measured in the blood and urine probably due to the modified regimen used in our study and to the organ insufficiency in this selected group of patients. Although, toxicity was generally mild and manageable, two toxic deaths occurred. In conclusion, this regimen appears to have a lower efficacy in terms of response and survival than that obtained in other studies using Cisplatin or Carboplatin plus Etoposide in a similar way. Therapy with this regimen, though less toxic, may not be a reliable alternative in elderly patients with visceral metastases and ECOG performance status > or = 2.en
heal.journalNameLung Canceren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Samantas-1999-Combination chemothe.pdf119.6 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.